Le Lézard
Classified in: Health
Subject: PDT

Focus Labs Debuts Their Revolutionary O3+Maquitm Supplements at the Historic Virtual ECRM Conference


FORT LAUDERDALE, Fla., July 3, 2020 /PR Newswire/ -- Focus Laboratories plans to expand the reach of their supplement sales, following a successful return from the historic all-virtual ECRM conference. The Efficient Collaborative Retail Marketing (ECRM) conference is an opportunity for established and emerging brands to meet with retailers in their field, in the hopes of having their products sold through some of the largest online and brick and mortar retailers in the United States.

May's program on Healthy Living, Vitamin, and Nutrition has been a stand-out event since social distancing procedures required the conference to be held entirely online. This sudden change in meeting format has done plenty to raise the value of brands who are able to adapt, and demonstrate significant tech-literacy, in what is being called the new age of business to business marketing.

Focus Labs showcased one of their premium products through a series of video conferences with prospective buyers in this novel and fast-paced presentation format, and their completely unique O3+Maquitmsupplements have made an impact.

O3+Maquitm supplements are comprised of a softgel capsule, filled with Omega-3 fish oil, and their signature ingredient, MaquiBright ®. MaquiBright ® is a derivative of the Maqui Berry, a revolutionary superfood that has been researched for its higher than average antioxidant content.

Maqui berries have been used in traditional medicine in their native Chile for centuries. They are considered to have a higher antioxidant count than known "superfoods" like blueberry and acai berry and are known for their beautiful purple pigment.

But perhaps the most unique aspect of Focus Labs' O3+Maquitm supplements is it's made using a patented Unigeltm Technology, which combines a liquid supplement and powder tablet within one softgel. The visual appeal of this supplement is stunning; a translucent amber-colored softgel capsule, with a small purple sphere suspended in the liquid.

This Unigeltm technology allows for the precise combination of two different types of supplements, which would otherwise need to be taken separately, since they are each most effective in different states. Omega-3 fish oil is only able to maintain its bioavailability as an unoxidized liquid, and MaquiBright ® is most useful to the body in its powder form. Through this breakthrough in supplement technology, these two powerful nutrients are able to move through the body in tandem, utilizing both to their fullest potential.

Focus Labs' O3+Maquitm brings a host of outstanding features to the table when it comes to meeting with retailers from across the United States, and after May's ECRM conference they are looking forward to a future of expansion online and in stores throughout 2020.

Please direct inquiries to:
Madeline Hollenbeck
(954) 439-2234
[email protected] 

SOURCE Focus Laboratories


These press releases may also interest you

at 03:00
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, today announced an oral presentation at the upcoming Oligonucleotide & Peptide Therapeutics (TIDES) Conference...

at 02:32
With every successive year, the lines between medical devices and consumer electronics become increasingly blurred ? medtech companies seek to expand their reach beyond patients, and consumer electronics companies have targeted medical applications...

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...



News published on and distributed by: